ANGPT2 and non-small cell lung carcinoma: In particular, the median overall survival was 10 months in stage IIIβ NSCLC patients with a high Ang-2 baseline level (95% CI: 1.8–18.2), while the median overall survival was 46 months in stage IIIβ NSCLC patients with a low Ang-2 baseline concentration (95% CI: 9.5–82.5) (p = 0.012, Figure 3A).